European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading

MT Newswires Live06-18

European equities traded in the US as American depositary receipts were moving slightly higher late Tuesday morning, rising 0.14% to 1,418.16 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion Biotech (EVAX) was up 11% and biopharmaceutical company Genfit (GNFT) added 3.4%. They were followed by oil and gas companies TotalEnergies (TTE) and Eni (E), which were both up 1.6%.

The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and telecommunications company VEON (VEON), which lost 9.4% and 3%, respectively. Biopharmaceutical company Cellectis (CLLS) retreated 1.9% and medical device maker EDAP TMS (EDAP) lost 1.5%.

From the UK and Ireland, the gainers were led by cruise line operator Carnival (CUK) and utilities company National Grid (NGG), which increased 2% and 1.5%, respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Akari Therapeutics (AKTX), which rose 1.1% and 1%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and Adaptimmune Therapeutics (ADAP), which fell 4.4% and 4.3%, respectively. Biotech firm Autolus Therapeutics (AUTL) was down 3.4%, while biopharmaceutical company Verona Pharma (VRNA) retreated 3.1%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment